

Mechanisms of cutaneous toxicities to EGFR inhibitors

Nature Reviews Cancer

6, 803-812

DOI: [10.1038/nrc1970](https://doi.org/10.1038/nrc1970)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New approaches to molecular cancer therapeutics. <i>Nature Chemical Biology</i> , 2006, 2, 689-700.	3.9	361
3	Non-Rash Skin Toxicities Associated with Novel Targeted Therapies. <i>Clinical Lung Cancer</i> , 2006, 8, S36-S42.	1.1	25
4	A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 4071-4076.	3.3	203
6	What Kind of Rash Is It?: Deciphering the Dermatologic Toxicities of Biologic and Targeted Therapies. <i>Clinical Journal of Oncology Nursing</i> , 2007, 11, 659-666.	0.3	19
7	Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 70.	3.8	141
8	Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers. <i>Oncologist</i> , 2007, 12, 1443-1455.	1.9	297
9	Severe Cutaneous Reaction during Radiation Therapy with Concurrent Cetuximab. <i>New England Journal of Medicine</i> , 2007, 357, 514-515.	13.9	116
10	Radiation-Induced Prevention of Erlotinib-Induced Skin Rash Is Transient: A New Aspect Toward the Understanding of Epidermal Growth Factor Receptor Inhibitor-Associated Cutaneous Adverse Effects. <i>Journal of Clinical Oncology</i> , 2007, 25, 4697-4698.	0.8	19
11	The Era of Targeted Therapies. <i>Archives of Dermatology</i> , 2007, 143, 788-9.	1.7	3
12	Temporal Dependence of the Effect of Radiation on Erlotinib-Induced Skin Rash. <i>Journal of Clinical Oncology</i> , 2007, 25, 2140-2140.	0.8	26
13	Targeting the Epidermal Growth Factor Receptor in Colorectal Carcinoma. <i>Cancer Nursing</i> , 2007, 30, S1-S9.	0.7	5
14	Insights Into the Pathophysiology and Management of Dermatologic Toxicities to EGFR-Targeted Therapies in Colorectal Cancer. <i>Cancer Nursing</i> , 2007, 30, S17-S26.	0.7	26
15	Epidermal Growth Factor Receptor Inhibitor-Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management. <i>Oncologist</i> , 2007, 12, 610-621.	1.9	318
16	Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. <i>Oncogene</i> , 2007, 26, 3291-3310.	2.6	2,421
17	Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. <i>Nature Reviews Cancer</i> , 2007, 7, 332-344.	12.8	720
18	Development and Management of Severe Cutaneous Side Effects in Head-and-Neck Cancer Patients during Concurrent Radiotherapy and Cetuximab. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 105-110.	1.0	64
19	Can we predict the response to epidermal growth factor receptor targeted therapy?. <i>Targeted Oncology</i> , 2008, 3, 87-99.	1.7	1
20	Management of skin toxicity of epidermal growth factor receptor inhibitors. <i>Targeted Oncology</i> , 2008, 3, 245-251.	1.7	5

#	ARTICLE	IF	CITATIONS
21	Molekulardiagnostik von Mutationen des epidermalen Wachstumsfaktor-Rezeptors und Aktivierung nachgeschalteter Signalwege in nichtkleinzelligen Lungenkarzinomen. <i>Onkopipeline</i> , 2008, 1, 101-108.	0.0	0
22	Rash from EGFR inhibitors: Opportunities and challenges for palliation. <i>Current Oncology Reports</i> , 2008, 10, 304-308.	1.8	17
23	Current aspects of targeted therapy in head and neck tumors. <i>European Archives of Oto-Rhino-Laryngology</i> , 2008, 265, 3-12.	0.8	38
24	Severe skin reaction secondary to concomitant radiotherapy plus cetuximab. <i>Radiation Oncology</i> , 2008, 3, 5.	1.2	29
25	Augmented sparse reconstruction of protein signaling networks. <i>Journal of Theoretical Biology</i> , 2008, 255, 40-52.	0.8	12
27	Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 21-30.	2.0	40
28	Gemcitabine Plus Paclitaxel may be a Promising Chemotherapy Regimen for Metastatic Granular Cell Tumour. <i>Clinical Oncology</i> , 2008, 20, 93-96.	0.6	8
29	Cetuximab is Effective, but more Toxic than Reported in the Bonner Trial. <i>Clinical Oncology</i> , 2008, 20, 96.	0.6	28
30	Drug reactions – New observations. <i>JDDG - Journal of the German Society of Dermatology</i> , 2008, 6, 508-509.	0.4	0
31	EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. <i>Nature Cell Biology</i> , 2008, 10, 902-911.	4.6	184
32	Redistribution of LRIG Proteins in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1192-1195.	0.3	19
33	The Epidermal Growth Factor Receptor System in Skin Repair and Inflammation. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1365-1374.	0.3	361
34	Unusual hair changes with prolonged erlotinib exposure. <i>Internal Medicine Journal</i> , 2008, 38, 807-807.	0.5	1
35	Targeted therapies for patients with germ cell tumors. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 511-522.	1.9	18
36	Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity: Mechanisms, Treatment, and its Potential Role as a Predictive Marker. <i>Clinical Colorectal Cancer</i> , 2008, 7, 33-43.	1.0	53
37	Completeness in the Reporting of Dermatologic Adverse Drug Reactions Associated with Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors in Phase II and III Colorectal Cancer Clinical Trials. <i>Clinical Colorectal Cancer</i> , 2008, 7, 309-314.	1.0	15
38	Promises borne out in clinical studies. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 15-24.	2.2	0
39	EGFR Antagonists in Cancer Treatment. <i>New England Journal of Medicine</i> , 2008, 358, 1160-1174.	13.9	1,869

#	ARTICLE	IF	CITATIONS
40	Cutaneous toxicities of targeted cancer therapies. <i>Community Oncology</i> , 2008, 5, 413-414.	0.2	3
41	Novel acquisitions on the immunoprotective roles of the EGF receptor in the skin. <i>Expert Review of Dermatology</i> , 2008, 3, 525-527.	0.3	18
42	Challenges in Combinational Oncology Studies. <i>Pharmaceutical Medicine</i> , 2008, 22, 85-97.	1.0	4
43	Severe Purpuric Xerotic Dermatitis Associated With Gefitinib Therapy. <i>Archives of Dermatology</i> , 2008, 144, 269-70.	1.7	16
44	Acitretin for Treatment of EGFR Inhibitor-Induced Cutaneous Toxic Effects. <i>Archives of Dermatology</i> , 2008, 144, 949-50.	1.7	20
45	Practical Management Recommendations for Anti-ErbB2 Therapy with Lapatinib. <i>Breast Care</i> , 2008, 3, 13-16.	0.8	3
46	The Koebner-Phenomenon in Epidermal Growth Factor Receptor Inhibitor-Induced Cutaneous Adverse Effects. <i>Journal of Clinical Oncology</i> , 2008, 26, 2790-2792.	0.8	22
47	An Interdisciplinary Consensus on Managing Skin Reactions Associated With Human Epidermal Growth Factor Receptor Inhibitors. <i>Clinical Journal of Oncology Nursing</i> , 2008, 12, 283-290.	0.3	58
48	Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2008, 19, 142-149.	0.6	190
49	Nursing Management of Epidermal Growth Factor Receptor Inhibitor-Induced Toxicities. <i>Clinical Journal of Oncology Nursing</i> , 2008, 12, 405-407.	0.3	5
50	Pigmented Olfactory Neuroblastoma: A CD56-Positive Mimic of Melanoma. <i>Archives of Dermatology</i> , 2008, 144, 270-2.	1.7	7
51	Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2779-2780.	0.8	42
52	Noninvasive Imaging and Quantification of Epidermal Growth Factor Receptor Kinase Activation <i>In vivo</i> . <i>Cancer Research</i> , 2008, 68, 4990-4997.	0.4	30
53	EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. <i>Pharmacogenomics</i> , 2008, 9, 55-69.	0.6	12
54	Current status of antivasular therapy and targeted treatment in the clinic. <i>International Journal of Hyperthermia</i> , 2008, 24, 97-110.	1.1	3
55	Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. <i>Current Opinion in Oncology</i> , 2008, 20, 256-263.	1.1	50
56	Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care. <i>Current Opinion in Supportive and Palliative Care</i> , 2008, 2, 19-21.	0.5	10
57	Targeted treatment of advanced and metastatic breast cancer with lapatinib. <i>OncoTargets and Therapy</i> , 2008, 1, 21.	1.0	1

#	ARTICLE	IF	CITATIONS
58	The Role of Inhibitors of the Epidermal Growth Factor in Management of Head and Neck Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 696-706.	2.3	12
60	Management of Skin Rash during egfr-Targeted Monoclonal Antibody Treatment for Gastrointestinal Malignancies: Canadian Recommendations. Current Oncology, 2009, 16, 16-26.	0.9	120
61	Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. Journal of Oncology, 2009, 2009, 1-8.	0.6	35
62	Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept. Journal of Oncology, 2009, 2009, 1-8.	0.6	36
63	Update on Anti-EGFR Targeted Therapy. Journal of Oncology, 2009, 2009, 1-2.	0.6	2
64	Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer. Cutaneous and Ocular Toxicology, 2009, 28, 41-44.	0.5	8
65	Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis. Oncology, 2009, 77, 124-133.	0.9	61
66	Desmoglein 1 –dependent suppression of EGFR signaling promotes epidermal differentiation and morphogenesis. Journal of Cell Biology, 2009, 185, 1243-1258.	2.3	186
67	Tumor Necrosis Factor- α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice. Cancer Research, 2009, 69, 5643-5647.	0.4	52
68	Molecular therapy in head and neck oncology. Nature Reviews Clinical Oncology, 2009, 6, 266-277.	12.5	86
69	Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nature Reviews Clinical Oncology, 2009, 6, 219-228.	12.5	182
70	Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer. Oncologist, 2009, 14, 478-488.	1.9	87
71	Evidence-Based Treatment Options for the Management of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors. Annals of Pharmacotherapy, 2009, 43, 1658-1666.	0.9	44
72	Dose-Dependent Increases in Circulating TGF- α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent. Clinical Cancer Research, 2009, 15, 2397-2405.	3.2	38
73	Expert Consensus on the Management of Erlotinib-Associated Cutaneous Toxicity in the U.K.. Oncologist, 2009, 14, 840-847.	1.9	37
74	Efectos secundarios cutáneos de los fármacos antineoplásicos (II): inhibidores de cinasas y anticuerpos monoclonales. Piel, 2009, 24, 427-439.	0.0	0
76	Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer, 2009, 115, 1544-1554.	2.0	127
77	Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer, 2009, 115, 1286-1299.	2.0	76

#	ARTICLE	IF	CITATIONS
78	Analysis of dermatologic events in patients with cancer treated with lapatinib. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 485-493.	1.1	78
79	Skin toxicities associated with epidermal growth factor receptor inhibitors. <i>Targeted Oncology</i> , 2009, 4, 107-119.	1.7	240
80	The keratinocyte in epidermal renewal and defence. <i>Veterinary Dermatology</i> , 2009, 20, 515-532.	0.4	52
81	Crosstalk of Notch with p53 and p63 in cancer growth control. <i>Nature Reviews Cancer</i> , 2009, 9, 587-595.	12.8	157
83	Trichomegaly in a 3-year-old Girl with Alopecia Areata. <i>Pediatric Dermatology</i> , 2009, 26, 188-193.	0.5	16
84	Selective antagonism of anticancer drugs for side-effect removal. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 403-410.	4.0	20
86	Recent advances of novel targeted therapy in non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2009, 2, 2.	6.9	69
89	Molecular Targeted Therapies for Solid Tumors: Management of Side Effects. <i>Oncology Research and Treatment</i> , 2009, 32, 129-138.	0.8	15
90	High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes. <i>Radiotherapy and Oncology</i> , 2009, 90, 166-171.	0.3	144
91	Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2009, 90, 172-176.	0.3	113
92	Skin toxicities of targeted therapies. <i>European Journal of Cancer</i> , 2009, 45, 295-308.	1.3	57
93	Side Effects of Molecularly Targeted Drugs and Their Molecular Mechanisms. <i>Journal of Health Science</i> , 2009, 55, 338-346.	0.9	0
94	NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, S-5-S-21.	2.3	102
95	Supportive care in head and neck oncology. <i>Current Opinion in Oncology</i> , 2010, 22, 221-225.	1.1	20
96	Histological and Immediate Postoperative Outcome after Preoperative Cetuximab: Case-Matched Control Study. <i>World Journal of Surgery</i> , 2010, 34, 2765-2772.	0.8	13
99	A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. <i>Supportive Care in Cancer</i> , 2010, 18, 509-522.	1.0	142
100	Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2010, 103, 987-992.	2.9	18
101	Targeted therapies in metastatic non-small cell lung cancer (NSCLC): the rational approach. <i>Current Oncology</i> , 2010, 17, 13-23.	0.9	64

#	ARTICLE	IF	CITATIONS
102	Systemic Therapies in Metastatic Non-Small-Cell Lung Cancer with Emphasis on Targeted Therapies: The Rational Approach. <i>Current Oncology</i> , 2010, 17, 13-23.	0.9	63
103	Predictive toxicology approaches for small molecule oncology drugs. , 0, , 204-229.		0
104	EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 185-201.	1.0	32
105	Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study. <i>Clinical Cancer Research</i> , 2010, 16, 2474-2482.	3.2	54
106	Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders. <i>Clinical Cancer Research</i> , 2010, 16, 1058-1064.	3.2	62
107	Effect and Risk of AEE788, a Dual Tyrosine Kinase Inhibitor, on Regeneration in a Rat Liver Resection Model. <i>European Surgical Research</i> , 2010, 44, 82-95.	0.6	6
108	Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1351-1357.	0.8	410
109	Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver. <i>Science Translational Medicine</i> , 2010, 2, 16ra7.	5.8	154
110	Predictive Toxicology Approaches for Small Molecule Oncology Drugs. <i>Toxicologic Pathology</i> , 2010, 38, 148-164.	0.9	17
111	Papulopustular Eruption Associated With Panitumumab. <i>Archives of Dermatology</i> , 2010, 146, 918.	1.7	28
112	Management of the Cutaneous Side Effects of Therapeutic Epidermal Growth Factor Receptor Inhibition. <i>Onkologie</i> , 2010, 33, 470-479.	1.1	14
113	Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy. <i>Journal of the National Cancer Institute</i> , 2010, 102, 47-53.	3.0	148
114	Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. <i>Experimental Biology and Medicine</i> , 2010, 235, 907-920.	1.1	41
115	Epigen Transgenic Mice Develop Enlarged Sebaceous Glands. <i>Journal of Investigative Dermatology</i> , 2010, 130, 623-626.	0.3	29
116	Treatment of Epidermal Growth Factor Receptor Antagonist-Induced Skin Rash: Results of a Survey among German Oncologists. <i>Onkologie</i> , 2010, 33, 94-98.	1.1	39
117	Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2010, 5, 142-151.	0.8	3
118	Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2363-2389.	0.9	19
119	Cutaneous consequences of inhibiting EGF receptor signaling in vivo: Normal hair follicle development, but retarded hair cycle induction and inhibition of adipocyte growth in <i>Egfr^{Wa5}</i> mice. <i>Journal of Dermatological Science</i> , 2010, 57, 155-161.	1.0	26

#	ARTICLE	IF	CITATIONS
120	Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab. <i>Clinical Pharmacokinetics</i> , 2010, 49, 729-740.	1.6	63
121	Cutaneous Crohn disease mimicking anal condylomata in a child. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 165-166.	0.6	10
122	Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 163-165.	0.6	39
123	Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. <i>European Journal of Cancer</i> , 2010, 46, 2010-2019.	1.3	71
124	A Prospective Crossover Pilot Study to Evaluate the Use of a Topical Wound Gel in Patients with Cutaneous Toxicity Caused by Epidermal Growth Factor Receptor Inhibitors. <i>The Journal of Supportive Oncology</i> , 2010, 8, 202-208.	2.3	7
125	Asymmetric Distribution of Epidermal Growth Factor Receptor Directs the Fate of Normal and Cancer Keratinocytes In Vitro. <i>Stem Cells and Development</i> , 2010, 19, 209-220.	1.1	22
127	Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours. <i>Acta Oncologica</i> , 2010, 49, 113-116.	0.8	13
128	Cetuximab-Associated Elongation of the Eyelashes. <i>American Journal of Clinical Dermatology</i> , 2011, 12, 63-67.	3.3	31
129	Drug-Induced Acneiform Eruption. <i>American Journal of Clinical Dermatology</i> , 2011, 12, 233-245.	3.3	57
130	Phenylbutyrate suppresses distinct skin reactions that are enhanced by blockade of epidermal growth factor receptor signaling. <i>Journal of Dermatological Science</i> , 2011, 64, 163-173.	1.0	6
132	Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts. <i>Clinics in Dermatology</i> , 2011, 29, 587-601.	0.8	19
133	Effect of adapalene on cetuximab-induced painful periungual inflammation. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, e20-e21.	0.6	16
134	Tyrosine kinases in inflammatory dermatologic disease. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 389-403.	0.6	7
135	Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). <i>Radiotherapy and Oncology</i> , 2011, 98, 38-41.	0.3	87
136	Successful Treatment of Epidermal Growth Factor Receptor Inhibitor-Induced Periungual Inflammation with Adapalene. <i>Case Reports in Dermatology</i> , 2011, 3, 130-136.	0.3	11
137	Unilateral onycholysis in a patient taking erlotinib (Tarceva). <i>BMJ Case Reports</i> , 2011, 2011, bcr0420114157-bcr0420114157.	0.2	2
138	Targeted Therapy in Patients With Non-small Cell Lung Cancer Previously Treated With Chemotherapy. <i>Medicina (Lithuania)</i> , 2011, 47, 520.	0.8	5
139	Reações cutâneas adversas aos inibidores do receptor do factor de crescimento epidérmico: estudo de 14 doentes. <i>Anais Brasileiros De Dermatologia</i> , 2011, 86, 483-490.	0.5	29

#	ARTICLE	IF	CITATIONS
140	Paronychia and Pyogenic Granuloma Induced by New Anticancer mTOR Inhibitors. <i>Acta Dermato-Venereologica</i> , 2011, 91, 584-585.	0.6	25
141	Preemptive Management of Dermatologic Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors. <i>Clinical Journal of Oncology Nursing</i> , 2011, 15, 501-508.	0.3	11
142	Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers. <i>Annals of Dermatology</i> , 2011, 23, 12.	0.3	3
143	Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. <i>Current Opinion in Oncology</i> , 2011, 23, 343-351.	1.1	32
144	Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. <i>International Journal of Dermatology</i> , 2011, 50, 129-146.	0.5	52
145	Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway. <i>British Journal of Dermatology</i> , 2011, 164, 38-46.	1.4	15
146	Higher severity grade of erlotinib-induced rash is associated with lower skin phototype. <i>Clinical and Experimental Dermatology</i> , 2011, 36, 733-738.	0.6	17
147	Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 195-202.	0.4	28
148	Management kutaner Nebenwirkungen von EGFR-Inhibitoren: Empfehlungen eines deutschen Expertengremiums für den primär behandelnden Arzt. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 195-203.	0.4	14
149	Cetuximab-associated folliculitis predominantly affecting the lower limbs. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 703-704.	0.4	3
150	Cetuximab-assoziierte Follikulitis mit überwiegendem Befall der unteren Extremitäten. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 703-704.	0.4	2
151	Adhesion molecule signalling: not always a sticky business. <i>Nature Reviews Molecular Cell Biology</i> , 2011, 12, 189-197.	16.1	228
152	Density of <i>Demodex folliculorum</i> in Patients Receiving Epidermal Growth Factor Receptor Inhibitors. <i>Dermatology</i> , 2011, 222, 144-147.	0.9	56
153	Molecular oncology in lung cancer – between biomarkers and clinical application. Relevance of the Ras-Raf-MEK-ERK pathway. <i>Memo - Magazine of European Medical Oncology</i> , 2011, 4, 242-247.	0.3	1
154	Rosacea: the Cytokine and Chemokine Network. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2011, 15, 40-47.	0.8	126
155	Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). <i>Investigational New Drugs</i> , 2011, 29, 1114-1121.	1.2	89
156	Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. <i>Supportive Care in Cancer</i> , 2011, 19, 1079-1095.	1.0	374
157	Establishment of A431 cell membrane chromatography-RPLC method for screening target components from <i>Radix Caulophylli</i> . <i>Journal of Separation Science</i> , 2011, 34, 508-513.	1.3	26

#	ARTICLE	IF	CITATIONS
158	Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile. <i>Cancer Biology and Therapy</i> , 2011, 11, 373-382.	1.5	127
162	Human Epidermal Growth Factor Eyedrops for Cetuximab-Related Filamentary Keratitis. <i>Journal of Clinical Oncology</i> , 2011, 29, e678-e679.	0.8	14
163	The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab. <i>Clinical Cancer Research</i> , 2011, 17, 6766-6777.	3.2	30
164	Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor. <i>Clinical Cancer Research</i> , 2011, 17, 5962-5972.	3.2	39
165	Economic Burden of Dermatologic Adverse Events Induced by Molecularly Targeted Cancer Agents. <i>Archives of Dermatology</i> , 2011, 147, 1403.	1.7	41
166	Off-Target Serine/Threonine Kinase 10 Inhibition by Erlotinib Enhances Lymphocytic Activity Leading to Severe Skin Disorders. <i>Molecular Pharmacology</i> , 2011, 80, 466-475.	1.0	43
167	Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy. <i>Oncologist</i> , 2011, 16, 228-238.	1.9	94
168	Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. <i>Annals of Oncology</i> , 2011, 22, 712-717.	0.6	67
169	Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. <i>Annals of Oncology</i> , 2011, 22, 524-535.	0.6	104
170	EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects. <i>Cancers</i> , 2011, 3, 2014-2031.	1.7	29
171	The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. <i>Annals of Oncology</i> , 2011, 22, 2366-2374.	0.6	24
172	Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S7340.	0.6	32
173	Effective therapy of epidermal growth factor receptor inhibitor-associated dermatologic side effects in a patient with metastatic colorectal cancer: a and review of literature. <i>Advances in Dermatology and Allergology</i> , 2012, 4, 324-329.	1.0	2
174	Supportive Care Treatments for Toxicities of Anti-EGFR and Other Targeted Agents. <i>Current Oncology</i> , 2012, 19, 59-63.	0.9	34
175	Risk of Rash in Cancer Patients Treated with Vandetanib: Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1125-1133.	1.8	45
177	The Black Box Illuminated: Signals and Signaling. <i>Journal of Investigative Dermatology</i> , 2012, 132, 811-819.	0.3	35
179	A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. <i>Annals of Oncology</i> , 2012, 23, 1081-1082.	0.6	4
180	Modeling the Transcriptional Consequences of Epidermal Growth Factor Receptor Ablation in Ras-Initiated Squamous Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 170-183.	3.2	3

#	ARTICLE	IF	CITATIONS
181	L'Éducation thérapeutique d'un patient atteint d'un cancer du poumon. Actualites Pharmaceutiques, 2012, 51, 8-9.	0.0	0
182	Prise en charge des toxicités des thérapies ciblées en oncologie thoracique. Revue Des Maladies Respiratoires Actualites, 2012, 4, 543-549.	0.0	0
183	Biologic therapies in the metastatic colorectal cancer treatment continuum – Applying current evidence to clinical practice. Cancer Treatment Reviews, 2012, 38, 397-406.	3.4	72
184	Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review. Cancer Treatment Reviews, 2012, 38, 505-514.	3.4	53
185	Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer, 2012, 12, 438.	1.1	30
186	The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis. Journal of the American Academy of Dermatology, 2012, 67, 400-408.	0.6	64
187	Management of dermatological toxicities in patients receiving EGFR inhibitors. Community Oncology, 2012, 9, 315-323.	0.2	1
188	Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials. Lung Cancer, 2012, 78, 8-15.	0.9	120
189	Prevention and management of major side effects of targeted agents in breast cancer. Critical Reviews in Oncology/Hematology, 2012, 84, e79-e85.	2.0	13
190	Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation. Journal of Experimental Medicine, 2012, 209, 1105-1119.	4.2	161
191	Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Research and Treatment, 2012, 135, 347-354.	1.1	34
192	Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 125-139.	0.8	11
193	Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis. European Journal of Clinical Pharmacology, 2012, 68, 561-569.	0.8	17
194	Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Supportive Care in Cancer, 2012, 20, 909-921.	1.0	45
195	The management of EGFR inhibitor adverse events: a case series and treatment paradigm. International Journal of Dermatology, 2012, 51, 223-232.	0.5	34
196	Advances in the Management of Cutaneous Toxicities of Targeted Therapies. Seminars in Oncology, 2012, 39, 227-240.	0.8	45
197	Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field. Clinical and Experimental Dermatology, 2012, 37, 922-924.	0.6	3
198	Molecular targeting agents in the context of primary chemoradiation strategies. Head and Neck, 2013, 35, 738-746.	0.9	4

#	ARTICLE	IF	CITATIONS
199	The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Supportive Care in Cancer, 2013, 21, 1033-1041.	1.0	37
200	Side Effects of Medical Cancer Therapy. , 2013, , .		4
201	Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 250-260.	1.0	1
202	The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Targeted Oncology, 2013, 8, 173-181.	1.7	102
203	Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic. American Journal of Clinical Dermatology, 2013, 14, 327-333.	3.3	130
204	Recent advances in the epidermal growth factor receptor/ligand system biology on skin homeostasis and keratinocyte stem cell regulation. Journal of Dermatological Science, 2013, 72, 81-86.	1.0	82
205	Skinflammation and Drug Toxicityâ€”A Delicate Balance. Science Translational Medicine, 2013, 5, 199fs33.	5.8	8
206	Genetic Ablation of Epidermal EGFR Reveals the Dynamic Origin of Adverse Effects of Anti-EGFR Therapy. Science Translational Medicine, 2013, 5, 199ra110.	5.8	90
207	Biological therapies in breast cancer: Common toxicities and management strategies. Breast, 2013, 22, 1009-1018.	0.9	26
208	Scalp Pustules in a Patient Receiving Chemotherapy. JAMA - Journal of the American Medical Association, 2013, 310, 1068.	3.8	3
209	Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. Pharmacogenomics Journal, 2013, 13, 181-188.	0.9	29
210	Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors. Journal of Medical Economics, 2013, 16, 221-230.	1.0	8
212	Risk of Rash Associated With Lenalidomide in Cancer Patients: A Systematic Review of the Literature and Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 424-429.	0.2	31
213	Dermatitis and Alopecia. , 2013, , 147-166.		0
214	Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. European Journal of Haematology, 2013, 90, 142-150.	1.1	34
215	Panitumumab in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2013, 13, 781-793.	1.1	5
216	Dermatologic Adverse Events to Targeted Therapies in Lower GI Cancers: Clinical Presentation and Management. Current Treatment Options in Oncology, 2013, 14, 389-404.	1.3	20
217	Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Review of Anticancer Therapy, 2013, 13, 721-728.	1.1	80

#	ARTICLE	IF	CITATIONS
218	New Molecular and Cellular Targets for Chemoprevention and Treatment of Skin Tumors by Plant Polyphenols: A Critical Review. <i>Current Medicinal Chemistry</i> , 2013, 20, 852-868.	1.2	1
219	Paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. <i>Journal of Oncology Pharmacy Practice</i> , 2013, 19, 273-278.	0.5	2
220	Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation. <i>Science Translational Medicine</i> , 2013, 5, 199ra111.	5.8	197
221	Pathobiology of Cancer Regimen-Related Toxicities. , 2013, , .		5
222	Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatazumab (AV-299) and Gefitinib. <i>Journal of Clinical Oncology</i> , 2013, 31, e335-e337.	0.8	6
223	Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel. <i>Cancer Management and Research</i> , 2013, 5, 401.	0.9	44
224	Spared Pre-irradiated Area in Pustular Lesions Induced by Icotinib Showing Decreased Expressions of CD1a+ Langerhans Cells and FGFR2. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 200-204.	0.6	6
225	Hair repigmentation associated with the use of lenalidomide: Graying may not be an irreversible process!. <i>Journal of Oncology Pharmacy Practice</i> , 2013, 19, 165-169.	0.5	23
226	The Epidermal Growth Factor Receptor Increases Cytokine Production and Cutaneous Inflammation in Response to Ultraviolet Irradiation. <i>ISRN Dermatology</i> , 2013, 2013, 1-11.	1.9	25
227	Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. <i>Dermatologic Therapy</i> , 2013, 26, 135-148.	0.8	43
228	Algorithm for dermocosmetic use in the management of cutaneous side effects associated with targeted therapy in oncology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1071-1080.	1.3	27
229	IL-33/IL-31 axis: A new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity. <i>Journal of Cellular Biochemistry</i> , 2013, 114, 2673-2676.	1.2	19
230	Adherence Issues for Oral Antineoplastics. <i>American Journal of Lifestyle Medicine</i> , 2013, 7, 206-222.	0.8	1
231	Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma. <i>Oncologist</i> , 2013, 18, 314-322.	1.9	192
232	Skin toxicity of targeted cancer agents: mechanisms and intervention. <i>Future Oncology</i> , 2013, 9, 1161-1170.	1.1	24
233	Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells. <i>Oncology Reports</i> , 2013, 29, 237-243.	1.2	21
234	Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e55128.	1.1	120
235	RASopathic Skin Eruptions during Vemurafenib Therapy. <i>PLoS ONE</i> , 2013, 8, e58721.	1.1	72

#	ARTICLE	IF	CITATIONS
236	Randomized double-blind trial of prophylactic topical Evozac® Calming Skin Spray for gefitinib-associated acne-like eruption. <i>OncoTargets and Therapy</i> , 2014, 7, 1261.	1.0	0
237	Successful Treatment with Adapalene for EGFR-TKI-induced Acneiform Eruptions. <i>Japanese Journal of Lung Cancer</i> , 2014, 54, 978-982.	0.0	5
238	Panitumumab: leading to better overall survival in metastatic colorectal cancer?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 535-548.	1.4	1
239	Retarded low–dose doxycycline for EGFR or MEK inhibitor–induced papulopustular rash. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1685-1689.	1.3	13
240	Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 563-570.	1.1	14
241	Treatment of capecitabine-induced hand-foot syndrome using a topical retinoid: A case report. <i>Oncology Letters</i> , 2014, 7, 444-448.	0.8	13
242	Pain related to cancer treatments and diagnostic procedures: a no man's land?. <i>Annals of Oncology</i> , 2014, 25, 1097-1106.	0.6	28
243	Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs. <i>Frontiers in Oncology</i> , 2014, 4, 238.	1.3	63
244	Risk of anti-EGFR monoclonal antibody-related skin rash: an up-to-date meta-analysis of 25 randomized controlled trials. <i>Journal of Chemotherapy</i> , 2014, 26, 359-368.	0.7	12
245	Association between <sc><i>EGFR</i></sc> gene polymorphisms, skin rash and response to anti–<sc>EGFR</sc> therapy in metastatic colorectal cancer patients. <i>Experimental Dermatology</i> , 2014, 23, 751-753.	1.4	19
246	Retrospective Review of Eyelash Number in Patients Who Have Undergone Full-Thickness Eyelid Resection. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2014, 30, 1-6.	0.4	4
247	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 535-549.	1.0	30
248	Rash to the mTOR Inhibitor Everolimus. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 266-271.	0.6	19
249	Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy. <i>Melanoma Research</i> , 2014, 24, 501-503.	0.6	11
250	MAP-kinase pathway up or down? Just look at the map of your patients!. <i>Melanoma Research</i> , 2014, 24, 421-423.	0.6	4
251	Epidermal growth factor receptor inhibitors selectively inhibit the expressions of human β -defensins induced by <i>Staphylococcus epidermidis</i> . <i>Journal of Dermatological Science</i> , 2014, 75, 94-99.	1.0	18
252	The P110 subunit of PI3-K is a therapeutic target of acacetin in skin cancer. <i>Carcinogenesis</i> , 2014, 35, 123-130.	1.3	33
253	Side Effects of Targeted Therapies: Rash. <i>Seminars in Oncology Nursing</i> , 2014, 30, 147-154.	0.7	8

#	ARTICLE	IF	CITATIONS
254	Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. <i>Archives of Toxicology</i> , 2014, 88, 1189-1203.	1.9	47
255	The efficacy of Pistacia Terebinthus soap in the treatment of cetuximab-induced skin toxicity. <i>Investigational New Drugs</i> , 2014, 32, 1295-1300.	1.2	12
256	Epithelial Inflammation Resulting from an Inherited Loss-of-Function Mutation in EGFR. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2570-2578.	0.3	71
257	Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. <i>European Journal of Cancer</i> , 2014, 50, 1855-1863.	1.3	46
259	Towards manageable toxicities from targeted lung cancer treatment. <i>Lung Cancer Management</i> , 2015, 4, 279-287.	1.5	0
260	The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations. <i>Scientific Reports</i> , 2015, 5, 12675.	1.6	17
261	More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds. <i>Biomarker Insights</i> , 2015, 10s3, BMI.S22436.	1.0	7
262	Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1355.	0.9	4
264	EGFR and NF- κ B: partners in cancer. <i>Trends in Molecular Medicine</i> , 2015, 21, 385-393.	3.5	180
265	Changes in sebum levels and the development of acneiform rash in patients with non-small cell lung cancer after treatment with EGFR inhibitors. <i>OncoTargets and Therapy</i> , 2015, 8, 259.	1.0	18
266	A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 1229-1236.	1.1	7
267	Adverse skin reactions during treatment with cetuximab plus radiotherapy: Multidisciplinary approach to minimize radio-chemotherapy interruption. <i>Journal of Dermatological Treatment</i> , 2015, 26, 183-187.	1.1	4
268	Mechanisms underlying skin disorders induced by EGFR inhibitors. <i>Molecular and Cellular Oncology</i> , 2015, 2, e1004969.	0.3	86
269	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 206-219.	2.0	22
270	Epidermal cell junctions and their regulation by p63 in health and disease. <i>Cell and Tissue Research</i> , 2015, 360, 513-528.	1.5	9
271	Cutaneous adverse effects of targeted therapies. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 203-218.	0.6	191
272	Evolution of targeted therapies in cancer: opportunities and challenges in the clinic. <i>Future Oncology</i> , 2015, 11, 279-293.	1.1	20
273	Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights. <i>Skin Appendage Disorders</i> , 2015, 1, 31-37.	0.5	63

#	ARTICLE	IF	CITATIONS
274	Efficacy of Prophylactic Minocycline Treatment for Skin Toxicities Induced by Erlotinib Plus Gemcitabine in Patients with Advanced Pancreatic Cancer: A Retrospective Study. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 221-229.	3.3	12
275	Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial. <i>Future Oncology</i> , 2015, 11, 421-429.	1.1	9
276	Suppressed rate of carcinogenesis and decreases in tumour volume and lung metastasis in CXCL14/BRAK transgenic mice. <i>Scientific Reports</i> , 2015, 5, 9083.	1.6	37
277	Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. <i>Drugs</i> , 2015, 75, 1335-1348.	4.9	104
278	Dysbiosis and Staphylococcus aureus Colonization Drives Inflammation in Atopic Dermatitis. <i>Immunity</i> , 2015, 42, 756-766.	6.6	428
279	iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 6080-6085.	3.3	121
280	Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 97-110.	1.0	7
281	Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status. <i>Drugs</i> , 2015, 75, 731-748.	4.9	18
282	Erlotinib-Induced Skin Inflammation Is IL-1 Mediated in KC-Tie2 Mice and Human Skin Organ Culture. <i>Journal of Investigative Dermatology</i> , 2015, 135, 910-913.	0.3	16
283	Incidence and risk of xerosis with targeted anticancer therapies. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 656-667.	0.6	39
284	Nail toxicities induced by systemic anticancer treatments. <i>Lancet Oncology</i> , The, 2015, 16, e181-e189.	5.1	139
285	Practical Management of Lenalidomide-Related Rash. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S64-S69.	0.2	29
286	Reply to: "Skin moisturization for xerosis related to targeted anticancer therapies". <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e35-e36.	0.6	0
287	Alopecia in patients treated with molecularly targeted anticancer therapies. <i>Annals of Oncology</i> , 2015, 26, 2496-2502.	0.6	48
288	Chemotherapy and Cutaneous Drug Reactions. , 2015, , 309-321.		1
289	Cutaneous Drug Eruptions. , 2015, , .		1
290	A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients. <i>AAPS Journal</i> , 2015, 17, 1483-1491.	2.2	7
291	Management of Dermatologic Complications of Lung Cancer Therapies. <i>Current Treatment Options in Oncology</i> , 2015, 16, 50.	1.3	13

#	ARTICLE	IF	CITATIONS
292	Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. <i>Future Oncology</i> , 2015, 11, 617-627.	1.1	61
293	Severe gastrointestinal bleeding in patients with locally advanced head and neck squamous cell carcinoma treated by concurrent radiotherapy and Cetuximab. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 177-184.	1.2	11
294	Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. <i>OncoTargets and Therapy</i> , 2016, 9, 1291.	1.0	8
295	Construction of differential mRNA-lncRNA crosstalk networks based on ceRNA hypothesis uncover key roles of lncRNAs implicated in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 85728-85740.	0.8	83
296	Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 887.	1.4	13
297	Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 407-415.	0.6	28
298	Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer. <i>Dermatologic Surgery</i> , 2016, 42, S40-S48.	0.4	8
299	Molecular targeting in combination with platinum-based chemoradiotherapy in head and neck cancer treatment. <i>Head and Neck</i> , 2016, 38, E2173-81.	0.9	6
300	Efficacy of clindamycin phosphate and benzoyl peroxide gel (DUAC [®]) in the treatment of EGFR inhibitors-associated acneiform eruption. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1436-1438.	1.3	2
301	Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. <i>Oncologist</i> , 2016, 21, 1483-1491.	1.9	64
302	A patient with acantholytic pustular purpuric eruption due to gefitinib successfully treated with systemic antibiotics. <i>Dermatologica Sinica</i> , 2016, 34, 166-167.	0.2	4
303	In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors. <i>Molecular Diversity</i> , 2016, 20, 729-739.	2.1	11
305	Gabapentin and pregabalin for the treatment of chronic pruritus. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 619-625.e6.	0.6	86
306	Epidermal growth factor promotes proliferation of dermal papilla cells via Notch signaling pathway. <i>Biochimie</i> , 2016, 127, 10-18.	1.3	37
307	Safety of gefitinib in non-small cell lung cancer treatment. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 993-1000.	1.0	14
308	Pre-Emptive or Reactive Treatment of Cutaneous Rash Induced by Epidermal Growth Factor Receptor Inhibitors: Does It Matter?. <i>Journal of Clinical Oncology</i> , 2016, 34, 774-776.	0.8	0
309	Computer-aided design, synthesis, and biological evaluation of new indole-2-carboxamide derivatives as PI3K/EGFR inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2685-2690.	1.0	27
310	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw037.	3.0	24

#	ARTICLE	IF	CITATIONS
311	Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1552-1560.	0.8	13
312	Balancing selectivity and efficacy of bispecific antibodies. <i>New Biotechnology</i> , 2016, 33, S58-S59.	2.4	0
313	Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients. <i>Toxicology and Applied Pharmacology</i> , 2016, 311, 113-116.	1.3	15
314	Cell autonomous or systemic EGFR blockade alters the immune environment in squamous cell carcinomas. <i>International Journal of Cancer</i> , 2016, 139, 2593-2597.	2.3	36
315	Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis. <i>Future Oncology</i> , 2016, 12, 2741-2753.	1.1	8
316	The safety of afatinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1563-1572.	1.0	15
317	Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) – c-MET Antibodies and Antibody-Drug Conjugates. <i>Journal of Biological Chemistry</i> , 2016, 291, 25106-25119.	1.6	66
318	Epidermal Growth Factor Promotes Proliferation and Migration of Follicular Outer Root Sheath Cells via Wnt/ β^2 -Catenin Signaling. <i>Cellular Physiology and Biochemistry</i> , 2016, 39, 360-370.	1.1	45
319	EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections. <i>Supportive Care in Cancer</i> , 2016, 24, 3943-3950.	1.0	33
320	Mechanisms of skin aging induced by EGFR inhibitors. <i>Supportive Care in Cancer</i> , 2016, 24, 4241-4248.	1.0	26
321	Manejo y prevención de efectos secundarios al empleo de un anticuerpo monoclonal inhibidor de la señal de los receptores del factor de crecimiento epidérmico. <i>Gaceta Mexicana De Oncología</i> , 2016, 15, 31-39.	0.0	0
322	Necrolytic Migratory Erythema-like Skin Lesion During Gefitinib Treatment. <i>JAMA Dermatology</i> , 2016, 152, 947.	2.0	6
323	A successful approach to overcome imatinib-induced skin toxicity in a GIST patient. <i>Anti-Cancer Drugs</i> , 2016, 27, 576-579.	0.7	1
324	Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2016, 175, 1166-1174.	1.4	40
325	Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy. <i>MAbs</i> , 2016, 8, 405-413.	2.6	15
326	Skin problems and EGFR-tyrosine kinase inhibitor. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 291-298.	0.6	82
327	EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor. <i>Cancer Research</i> , 2016, 76, 1591-1602.	0.4	103
328	Cutaneous Manifestations of Chemotherapeutic Drugs. <i>Current Dermatology Reports</i> , 2016, 5, 58-69.	1.1	4

#	ARTICLE	IF	CITATIONS
329	Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1077-1085.	0.6	33
330	Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 100-104.	1.3	29
331	Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. <i>Supportive Care in Cancer</i> , 2016, 24, 301-309.	1.0	11
332	Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients. <i>International Journal of Clinical Oncology</i> , 2016, 21, 248-253.	1.0	5
333	Chemokine CXCL14 is a multistep tumor suppressor. <i>Journal of Oral Biosciences</i> , 2016, 58, 16-22.	0.8	3
334	Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer. <i>Journal of Dermatological Treatment</i> , 2016, 27, 148-152.	1.1	5
335	Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters. <i>Pharmacogenomics Journal</i> , 2017, 17, 325-330.	0.9	31
336	Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. <i>Scientific Reports</i> , 2017, 7, 40098.	1.6	85
337	Resveratrol mediates cell cycle arrest and cell death in human esophageal squamous cell carcinoma by directly targeting the EGFR signaling pathway. <i>Oncology Letters</i> , 2017, 13, 347-355.	0.8	14
338	Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. <i>Supportive Care in Cancer</i> , 2017, 25, 2179-2185.	1.0	17
339	Chemotherapy-induced alopecia management: Clinical experience and practical advice. <i>Journal of Cosmetic Dermatology</i> , 2017, 16, 537-541.	0.8	53
340	Dermatologic Reactions to Targeted Therapy. <i>Nursing Clinics of North America</i> , 2017, 52, 83-113.	0.7	14
341	Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 102-113.	2.0	32
342	Mitigation of epidermal growth factor receptor inhibitor-induced side effects utilizing melanin and vascular-specific lasers: A case report series. <i>Journal of Cosmetic and Laser Therapy</i> , 2017, 19, 300-302.	0.3	1
343	Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 413-423.	0.8	21
345	Emerging Cancer Biomarkers for HNSCC Detection and Therapeutic Intervention. , 2017, , 281-308.		1
346	ERBB2 Is Essential for the Growth of Chemically Induced Skin Tumors in Mice. <i>Journal of Investigative Dermatology</i> , 2017, 137, 921-930.	0.3	20
347	Toxicidad podológica de los tratamientos antineoplásicos. <i>EMC - Podología</i> , 2017, 19, 1-11.	0.1	0

#	ARTICLE	IF	CITATIONS
348	<sc>CRISPR</sc>â€ assisted receptor deletion reveals distinct roles for <sc>ERBB</sc>2 and <sc>ERBB</sc>3 in skin keratinocytes. FEBS Journal, 2017, 284, 3339-3349.	2.2	10
349	Effects of Colloidal Oatmeal Lotion on Symptoms of Dermatologic Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors. Advances in Skin and Wound Care, 2017, 30, 27-34.	0.5	0
350	EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management. Oncology and Therapy, 2017, 5, 135-148.	1.0	29
351	E-cadherin integrates mechanotransduction and EGFR signaling to control junctional tissue polarization and tight junction positioning. Nature Communications, 2017, 8, 1250.	5.8	147
352	Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients. Dermatology and Therapy, 2017, 7, 133-141.	1.4	7
353	Assessment of demodex presence in acne-like rash associated with cetuximab. Cutaneous and Ocular Toxicology, 2017, 36, 220-223.	0.5	6
354	Drug-induced acne. Clinics in Dermatology, 2017, 35, 156-162.	0.8	54
355	Clinical assessment of rosacea severity: oriental score vs. quantitative assessment method with imaging and biomedical tools. Skin Research and Technology, 2017, 23, 186-193.	0.8	11
356	Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Supportive Care in Cancer, 2017, 25, 651-660.	1.0	40
357	A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. Cancer Research, 2017, 77, 557-565.	0.4	10
359	Prevention and treatment of acute and chronic radiodermatitis. Breast Cancer: Targets and Therapy, 2017, Volume 9, 551-557.	1.0	27
360	The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors. Postepy Dermatologii I Alergologii, 2017, 5, 418-428.	0.4	18
361	Safety and General Considerations for the Use of Antibodies in Infectious Diseases. Advances in Experimental Medicine and Biology, 2017, 1053, 265-294.	0.8	1
362	Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan® research database. Supportive Care in Cancer, 2018, 26, 2369-2377.	1.0	1
363	Tunable cytotoxic aptamerâ€ drug conjugates for the treatment of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4761-4766.	3.3	108
364	â€No pain, No gainâ€ still true with immunotherapy: When the finger shows the moon, look at the moon!. Critical Reviews in Oncology/Hematology, 2018, 127, 1-5.	2.0	4
365	Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. Oncologist, 2018, 23, 891-899.	1.9	36
366	Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis. International Journal of Clinical Oncology, 2018, 23, 443-451.	1.0	10

#	ARTICLE	IF	CITATIONS
367	Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?. <i>Cancer Medicine</i> , 2018, 7, 317-324.	1.3	11
368	Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 1102-1109.	0.6	22
369	Management and grading of EGFR inhibitor-induced cutaneous toxicity. <i>Future Oncology</i> , 2018, 14, 2531-2541.	1.1	26
370	The receptor tyrosine kinase ERBB4 is expressed in skin keratinocytes and influences epidermal proliferation. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018, 1862, 958-966.	1.1	17
371	Taking it in the chin: vitamin K1 for the prevention of acneiform rash. <i>Annals of Oncology</i> , 2018, 29, 796-798.	0.6	0
372	Toward a Ferrous Iron-Cleavable Linker for Antibody-Drug Conjugates. <i>Molecular Pharmaceutics</i> , 2018, 15, 2054-2059.	2.3	12
373	Management of Toxicities of Targeted Therapies. , 2018, , 490-500.e3.		2
374	A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies. <i>Supportive Care in Cancer</i> , 2018, 26, 1169-1179.	1.0	17
375	Cetuximab-induced epidermolysis revealed by multiple erosions. <i>European Journal of Dermatology</i> , 2018, 28, 524-525.	0.3	2
376	Epidermal Growth Factor Immunotherapy: Exploring the Effects of NB-UVB Exposure.. , 2018, 08, .		0
377	Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1197-1209.	1.0	11
378	Anticancer Therapies. , 0, , 604-616.		0
379	Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. <i>BioScience Trends</i> , 2018, 12, 537-552.	1.1	20
380	In vitro and ex-vivo evaluation of topical formulations designed to minimize transdermal absorption of Vitamin K1. <i>PLoS ONE</i> , 2018, 13, e0204531.	1.1	4
381	Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6633-6646.	1.0	1
382	Simultaneous evaluation of anti-EGFR-induced tumour and adverse skin effects in a microfluidic human 3D co-culture model. <i>Scientific Reports</i> , 2018, 8, 15010.	1.6	56
383	Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. <i>Cancer Medicine</i> , 2018, 7, 5478-5487.	1.3	19
384	Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 31-39.	3.3	208

#	ARTICLE	IF	CITATIONS
385	Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors. <i>Drugs in Context</i> , 2018, 7, 1-11.	1.0	20
386	Modulating Aptamer Specificity with pH-Responsive DNA Bonds. <i>Journal of the American Chemical Society</i> , 2018, 140, 13335-13339.	6.6	97
387	Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: a meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 665-675.	1.0	10
388	BLIMP1 transcriptionally induced by EGFR activation and post-translationally regulated by proteasome and lysosome is involved in keratinocyte differentiation, migration and inflammation. <i>Journal of Dermatological Science</i> , 2018, 92, 151-161.	1.0	8
389	Dermatologic Side Effects of Systemic Targeted Anticancer Therapy. , 2018, , 285-313.		0
390	Nail Reactions to Anticancer Therapies. , 2018, , 439-451.		1
391	P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. <i>Journal of Controlled Release</i> , 2018, 286, 289-300.	4.8	18
392	Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 571-583.	1.1	13
393	The AHR represses nucleotide excision repair and apoptosis and contributes to UV-induced skin carcinogenesis. <i>Cell Death and Differentiation</i> , 2018, 25, 1823-1836.	5.0	56
394	TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1648-1658.	1.9	64
395	Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. <i>Future Oncology</i> , 2018, 14, 2437-2459.	1.1	7
396	Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival. <i>Oncology Research</i> , 2018, 26, 59-69.	0.6	8
397	Severe Pain Due to Paraspinal Abscess Formation in Two Patients with Squamous-Cell Carcinoma of the Head and Neck after Multimodal Treatment Including Cetuximab. <i>Oncology Research and Treatment</i> , 2018, 41, 395-398.	0.8	1
398	Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Oncology</i> , 2018, 95, 251-256.	0.9	11
399	Twenty years of adverse drug reactions: a look back – part 1. <i>Adverse Drug Reaction Bulletin</i> , 2018, 309, 1195-1198.	0.6	0
400	Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants. <i>ACS Chemical Biology</i> , 2019, 14, 1930-1939.	1.6	17
401	Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials. <i>Cancer Investigation</i> , 2019, 37, 253-264.	0.6	4
402	Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 1862.	2.2	86

#	ARTICLE	IF	CITATIONS
403	Novel functions of inactive rhomboid proteins in immunity and disease. <i>Journal of Leukocyte Biology</i> , 2019, 106, 823-835.	1.5	19
404	Predictive Biomarkers for Monoclonal Antibody Therapies Targeting EGFR (Cetuximab, Panitumumab) in the Treatment of Metastatic Colorectal Cancer. , 2019, , .		2
405	Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands. <i>Oncology Research</i> , 2019, 27, 551-556.	0.6	7
406	Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer. <i>Clinical Drug Investigation</i> , 2019, 39, 825-834.	1.1	17
407	Chinese herbal medicine for epidermal growth factor receptor inhibitor-induced skin rash in patients with malignancy: An updated meta-analysis of 23 randomized controlled trials. <i>Complementary Therapies in Medicine</i> , 2019, 47, 102167.	1.3	6
408	Preventive effect of Diallyl Trisulfide on cutaneous toxicities induced by EGFR inhibitor. <i>International Immunopharmacology</i> , 2019, 69, 79-87.	1.7	7
409	YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2575-2587.	3.2	71
410	Preclinical Evaluation of ¹¹¹ In-Labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-Positive Cancer Models. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1103-1110.	2.8	22
411	Titanium dioxide nanoparticles induce apoptosis by interfering with EGFR signaling in human breast cancer cells. <i>Environmental Research</i> , 2019, 175, 117-123.	3.7	28
412	Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft. <i>Oncotarget</i> , 2019, 10, 1031-1044.	0.8	14
413	Ibrutinib-associated palmo-plantar fissures in a patient with Chronic Lymphocytic Leukaemia: a novel cutaneous adverse event. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e342-e344.	1.3	5
414	The 10th International Congress on Cutaneous Adverse Drug Reactions, Shimane, Japan, 2018: Focus on New Discoveries. <i>Drug Safety</i> , 2019, 42, 797-801.	1.4	2
415	An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1225-1235.	1.0	9
416	Host-microbial dialogues in atopic dermatitis. <i>International Immunology</i> , 2019, 31, 449-456.	1.8	14
417	Prophylactic Dermatologic Treatment of Afatinib-Induced Skin Toxicities in Patients with Metastatic Lung Cancer: A Pilot Study. <i>Scientifica</i> , 2019, 2019, 1-6.	0.6	5
418	Pruritus in Patients Under Targeted Anticancer Therapy: A Multidimensional Analysis Using the 5-D Itch Scale. <i>Acta Dermato-Venereologica</i> , 2019, 99, 435-441.	0.6	4
419	Adverse Drug Reactions Involving Protein Kinase Inhibitors: A French Pharmacovigilance Database Study Comparing Safety in Younger and Older Patients (≥75 years) with Cancer. <i>Pharmaceutical Medicine</i> , 2019, 33, 21-27.	1.0	3
420	Reproductive toxicity of perchlorate in rats. <i>Food and Chemical Toxicology</i> , 2019, 128, 212-222.	1.8	16

#	ARTICLE	IF	CITATIONS
421	Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. <i>Seminars in Cancer Biology</i> , 2019, 59, 3-22.	4.3	29
422	Pertuzumab in HER2-positive early breast cancer: current use and perspectives. <i>Future Oncology</i> , 2019, 15, 1823-1843.	1.1	14
423	Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling. <i>Pharmaceuticals</i> , 2019, 12, 165.	1.7	1
424	Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 1271-1281.	0.6	18
425	Epidermal growth factor receptor (EGFR) inhibitor induced purpuric drug eruption. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.4	3
426	Differential Gene Expression in Erlotinib-Treated Fibroblasts. <i>Nursing Research</i> , 2019, 68, 110-126.	0.8	1
427	EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 278.	1.2	16
428	Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	23
429	Synthesis, Characterization and <i>in vitro</i> Studies of a Cathepsin B-Cleavable Prodrug of the VEGFR Inhibitor Sunitinib. <i>Chemistry and Biodiversity</i> , 2019, 16, e1800520.	1.0	9
430	Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption. <i>Journal of Dermatology</i> , 2019, 46, 18-25.	0.6	8
431	Clinical experience of chinese herbal medicine ameliorates dermatologic events from epidermal growth factor receptor inhibitors for lung cancer: A case series. <i>Explore: the Journal of Science and Healing</i> , 2019, 15, 363-370.	0.4	4
432	Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology. <i>Drug Safety</i> , 2019, 42, 181-198.	1.4	64
433	Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 129, 110-111.	0.9	9
434	Targeted therapy use in adults with cancer ≥85 years of age. <i>Geriatric Nursing</i> , 2019, 40, 63-66.	0.9	1
435	Case of purpuric drug eruption probably induced by panitumumab. <i>Journal of Dermatology</i> , 2019, 46, e221-e222.	0.6	1
436	Dermatologic Toxicities of Anticancer Therapy. , 2020, , 621-648.e5.		3
437	Increased infection rates associated with tetracycline therapy given for epidermal growth factor receptor inhibitor (EGFRI)-associated acneiform eruption: A retrospective study of data from two cancer centers. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 486-488.	0.6	1
438	Analysis of skin dose distribution for the prediction of severe radiation dermatitis in head and neck squamous cell carcinoma patients treated with concurrent chemo-radiotherapy. <i>Head and Neck</i> , 2020, 42, 244-253.	0.9	7

#	ARTICLE	IF	CITATIONS
439	Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival. <i>Autoimmunity Reviews</i> , 2020, 19, 102456.	2.5	12
440	Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash. <i>Journal of Dermatology</i> , 2020, 47, 121-127.	0.6	10
441	Targeted therapy in oncology patients and skin: Pharmaceutical and dermatocosmetic management. <i>Journal of Cosmetic Dermatology</i> , 2020, 19, 782-788.	0.8	6
442	Gefitinib-Induced Cutaneous Toxicities in Brown Norway Rats Are Associated with Macrophage Infiltration. <i>Inflammation</i> , 2020, 43, 2137-2146.	1.7	7
443	Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives. <i>Biomolecules</i> , 2020, 10, 1374.	1.8	40
444	Alkaescent soda beverage caused the disappearance of gefitinib-induced rashes and decreased efficacy in a non-small-cell lung cancer patient treated with gefitinib: A case report. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101228.	0.2	0
445	Dermatological side effects of targeted antineoplastic therapies: a prospective study. <i>Cutaneous and Ocular Toxicology</i> , 2020, 39, 380-384.	0.5	7
446	Human skin biomarkers relationship to response to treatment with tyrosine kinase inhibitors in advanced EGFR-mutated lung adenocarcinoma. <i>Thoracic Cancer</i> , 2020, 11, 3243-3251.	0.8	1
447	Association of dry skin with intercellular lipid composition of stratum corneum after erlotinib administration. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 233-243.	1.1	3
448	Citrus sudachi Peel Extract Suppresses Cell Proliferation and Promotes the Differentiation of Keratinocytes through Inhibition of the EGFR-ERK Signaling Pathway. <i>Biomolecules</i> , 2020, 10, 1468.	1.8	7
449	ONS Guidelines for Cancer Treatment-Related Skin Toxicity. <i>Oncology Nursing Forum</i> , 2020, 47, 539-556.	0.5	9
450	Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX). <i>Oncolimmunology</i> , 2020, 9, 1848058.	2.1	5
451	rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects. <i>Cancers</i> , 2020, 12, 3120.	1.7	8
452	An Aptamer for Broad Cancer Targeting and Therapy. <i>Cancers</i> , 2020, 12, 3217.	1.7	13
453	First- and third-generation epidermal growth factor receptor inhibitors mediate distinct phosphoprotein signalling networks: implications for adverse dermatological reactions. <i>British Journal of Dermatology</i> , 2020, 183, 1105-1107.	1.4	0
454	Nanoscale image of the drug/metal mono-layer interaction: Tapping AFM-IR investigations. <i>Nano Research</i> , 2020, 13, 1020-1028.	5.8	18
455	Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer. <i>Medicine (United States)</i> , 2020, 99, e20510.	0.4	18
456	Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies. <i>Biochemistry</i> , 2020, 59, 1428-1441.	1.2	35

#	ARTICLE	IF	CITATIONS
457	Purpuric drug eruptions induced by EGFR tyrosine kinase inhibitors are associated with IQGAP1-mediated increase in vascular permeability. <i>Journal of Pathology</i> , 2020, 250, 452-463.	2.1	7
458	Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients' Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers. <i>Clinical Colorectal Cancer</i> , 2020, 19, 100-108.e9.	1.0	11
459	Ibrutinib-Induced Vasculitis in a Patient with Metastatic Colon Cancer Treated in Combination with Cetuximab. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-4.	0.2	4
460	Relationships between quality of life and skin toxicities of epidermal growth factor receptor inhibitors in cancer patients: A literature review. <i>Japan Journal of Nursing Science</i> , 2020, 17, e12321.	0.5	6
461	Network pharmacology-based preventive effect of XZF on cutaneous toxicities induced by EGFR inhibitor. <i>Biomedicine and Pharmacotherapy</i> , 2020, 123, 109755.	2.5	8
462	EGFR-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy. <i>Supportive Care in Cancer</i> , 2020, 28, 4771-4779.	1.0	7
463	Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 589-599.	1.0	13
465	A case of unexpected peripherally inserted central catheter removal from a colorectal cancer patient with cetuximab-induced skin toxicity and contact dermatitis at the peripherally inserted central catheter insertion site: Should we recommend the patient to choose subcutaneous port preferentially?. <i>Journal of Vascular Access</i> , 2021, 22, 310-313.	0.5	3
466	Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib. <i>Toxicology Letters</i> , 2021, 338, 1-9.	0.4	5
467	Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines†. <i>Annals of Oncology</i> , 2021, 32, 157-170.	0.6	65
468	Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 404-411.	1.1	1
469	Prospective practice survey of management of cetuximab-related skin reactions. <i>Supportive Care in Cancer</i> , 2021, 29, 3497-3506.	1.0	1
470	Case of acquired reactive perforating collagenosis induced by panitumumab for colon cancer. <i>Journal of Dermatology</i> , 2021, 48, e114-e115.	0.6	4
471	Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512). <i>Supportive Care in Cancer</i> , 2021, 29, 2327-2334.	1.0	2
472	Microbial and Enzymatic Bioconversion of Tannery Wastes: Progress Toward a Circular Economy in the Leather Industry. , 2021, , 387-415.		0
473	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. <i>Supportive Care in Cancer</i> , 2021, 29, 3971-3980.	1.0	4
474	Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer. <i>Dermatology</i> , 2021, 237, 1-5.	0.9	9
475	Bioinformatic analysis of key pathways and genes involved in pediatric atopic dermatitis. <i>Bioscience Reports</i> , 2021, 41, .	1.1	3

#	ARTICLE	IF	CITATIONS
476	Eczematous Drug Eruptions. American Journal of Clinical Dermatology, 2021, 22, 349-366.	3.3	9
477	Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine. Medicine (United States), 2021, 100, e24292.	0.4	3
478	Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. Cancer Discovery, 2021, 11, 1672-1687.	7.7	112
479	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discovery, 2021, 11, 1688-1699.	7.7	154
480	Potential of Drug Efficacy Evaluation in Lung and Kidney Cancer Models Using Organ-on-a-Chip Technology. Micromachines, 2021, 12, 215.	1.4	12
481	Stomatitis associated with osimertinib in advanced lung cancer treatment: Characterization and implications for management. Lung Cancer, 2021, 152, 185-188.	0.9	2
482	Pemigatinib-induced nail changes – A case report. Journal of Oncology Pharmacy Practice, 2021, 27, 1795-1798.	0.5	2
483	Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial. Journal of Dermatology, 2021, 48, 1077-1080.	0.6	2
484	Design and Synthesis of Non-Covalent Imidazo[1,2-a]quinoxaline-Based Inhibitors of EGFR and Their Anti-Cancer Assessment. Molecules, 2021, 26, 1490.	1.7	13
485	Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy. Cancer Discovery, 2021, 11, 2158-2167.	7.7	10
486	Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 825-838.	0.9	15
487	Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity. Oncotarget, 2021, 12, 982-995.	0.8	0
488	Asymptomatic Purpuric Eruption on the Scalp of a Middle-aged Man. JAMA Oncology, 2021, 7, 771.	3.4	0
489	Oxidative stress induces EGFR inhibition-related skin cell death. Journal of Clinical Biochemistry and Nutrition, 2021, 68, 235-242.	0.6	4
490	Unlocking the Mechanisms of Cutaneous Adverse Drug Reactions: Activation of the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway by EGFR Inhibitors Triggers Keratinocyte Differentiation and Polarization of Epidermal Immune Responses. JID Innovations, 2021, 1, 100009.	1.2	2
491	Purchase of prophylactic topical corticosteroids is associated with improved survival in NSCLCs treated with EGFR TKI: real-world cohort study. Acta Oncologica, 2021, 60, 1100-1105.	0.8	1
492	Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR-Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. Frontiers in Medicine, 2021, 8, 570921.	1.2	2
493	Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products. Clinical Pharmacology in Drug Development, 2021, 10, 1028-1043.	0.8	11

#	ARTICLE	IF	CITATIONS
494	A Critical Review of Second-Generation Anti-EGFR Monoclonal Antibodies in Metastatic Colorectal Cancer. <i>Current Drug Targets</i> , 2021, 22, 1034-1042.	1.0	0
495	Review of chemotherapy-associated paronychia. <i>International Journal of Dermatology</i> , 2022, 61, 410-415.	0.5	5
496	Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103376.	2.0	9
497	Epithelial-immune crosstalk with the skin microbiota in homeostasis and atopic dermatitis – a mini review. <i>Veterinary Dermatology</i> , 2021, 32, 533.	0.4	5
498	Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2621-2627.	1.0	5
499	Cutaneous toxicities from targeted therapies used in oncology: literature review of clinical presentation and management. <i>International Journal of Women's Dermatology</i> , 2021, 7, 615-624.	1.1	3
500	Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 2007-2009.	0.5	3
501	Desmosomes as Signaling Hubs in the Regulation of Cell Behavior. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 745670.	1.8	34
502	EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function. <i>BMC Cancer</i> , 2021, 21, 5.	1.1	15
505	Immune-Related Oral, Otologic, and Ocular Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 295-307.	0.8	10
506	Biomarkers for Individualized Oral Cancer Therapy. , 2015, , 43-60.		1
508	Dermatologic Toxicities of Anticancer Therapy. , 2014, , 648-675.e4.		2
509	Gefitinib-induced hair alterations. <i>BMJ Case Reports</i> , 2009, 2009, bcr0920080878-bcr0920080878.	0.2	4
510	IL-36 β drives skin toxicity induced by EGFR/MEK inhibition and commensal <i>Cutibacterium acnes</i> . <i>Journal of Clinical Investigation</i> , 2020, 130, 1417-1430.	3.9	33
511	Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor. <i>PLoS ONE</i> , 2012, 7, e39706.	1.1	27
512	Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia. <i>PLoS ONE</i> , 2013, 8, e69368.	1.1	18
513	Lenalidomide Desensitization in Systemic Light-Chain Amyloidosis With Multi-Organ Involvement. <i>Journal of Clinical Medicine Research</i> , 2015, 7, 807-811.	0.6	4
514	Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin. <i>Oncotarget</i> , 2016, 7, 47777-47793.	0.8	33

#	ARTICLE	IF	CITATIONS
515	Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash. <i>Oncotarget</i> , 2017, 8, 35193-35204.	0.8	10
516	Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. <i>Oncotarget</i> , 2017, 8, 58709-58727.	0.8	37
517	Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. <i>Oncotarget</i> , 2018, 9, 18540-18547.	0.8	15
518	Treatment strategies of epidermal growth factor receptor inhibitor-induced skin toxicities: pre-emptive or reactive?. <i>Annals of Translational Medicine</i> , 2016, 4, 318-318.	0.7	3
519	Usefulness of Rapid Desensitization Therapy for Severe Rash Caused by Molecularly Targeted Drugs Used in the Treatment of Non-small-cell Lung Cancer. <i>Internal Medicine</i> , 2020, 59, 3201-3205.	0.3	1
520	Erlotinib-induced Adverse Skin Reactions. <i>The Open Allergy Journal</i> , 2013, 6, 22-29.	0.5	1
521	Physiological Change in Cutaneous Toxicity Related to Epidermal Growth Factor Receptor (EGFR) Inhibitors and the Efficacy of Emollient. <i>Nishinon Journal of Dermatology</i> , 2014, 76, 242-247.	0.0	3
522	Effective Supportive Care for Patients with Different Physiological Changes in Various Skin Regions Induced by EGFR Inhibitors. <i>Nishinon Journal of Dermatology</i> , 2015, 77, 399-405.	0.0	2
523	Erlotinib induced ectropion following papulopustular rash. <i>Journal of Dermatological Case Reports</i> , 2015, 9, 46-8.	1.1	6
524	Unseiin, a Kampo medicine, Reduces the Severity and Manifestations of Skin Toxicities Induced by Cetuximab: A Case Report. <i>Yonago Acta Medica</i> , 2020, 63, 379-384.	0.3	2
525	The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients. <i>Biomedicines</i> , 2021, 9, 2.	1.4	3
526	A Treatment Combination of IGF and EGF Promotes Hair Growth in the Angora Rabbit. <i>Genes</i> , 2021, 12, 24.	1.0	17
527	Dermatological side effects of epidermal growth factor receptor inhibitors: the "Pride" complex. <i>Indian Journal of Dermatology</i> , 2014, 59, 271.	0.1	32
528	A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients. <i>Indian Journal of Medical Research</i> , 2019, 150, 67.	0.4	12
529	Assessing health-related quality of life in cancer trials. <i>Clinical Investigation</i> , 2012, 2, 563-577.	0.0	7
530	Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature. <i>Drugs in Context</i> , 2019, 8, 1-7.	1.0	20
531	Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, e214761.	3.4	160
532	Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112297.	2.5	4

#	ARTICLE	IF	CITATIONS
533	Necrolytic migratory erythema-like eruptions induced by zinc deficiency during osimertinib treatment of EGFR-mutant non-small cell lung cancer: A case report. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100121.	0.1	0
534	Biologics for Colorectal Cancer Metastases. , 2009, , 1-7.		0
535	Contributions of Targeted Agents. <i>Medical Radiology</i> , 2009, , 215-223.	0.0	0
536	Kutane Nebenwirkungen unter Therapie mit EGFR-Inhibitoren. <i>Fortschritte Der Praktischen Dermatologie Und Venerologie</i> , 2009, , 248-251.	0.0	0
537	Biologisch zielgerichtete medikamentöse Therapie. , 2010, , 265-275.		0
538	Wrapper Drugs as Therapeutic Editors of Side Effects. , 2010, , 197-210.		0
540	Effects and Therapeutic Potential of Targeting Dysregulated Signaling Axes in Squamous Cell Carcinoma: Another Kinase of Transcription and Mammalian Target of Rapamycin. , 2011, , 383-405.		0
541	Dermatologic Manifestations of Systemic Oncologic Therapy of Cutaneous Malignancies. , 2011, , 379-385.		0
542	EGFR Signaling and Radiation. , 2011, , 201-226.		0
544	Drug and acneiform eruptions. , 2011, , 166-176.		0
545	Drug and acneiform eruptions. , 2011, , 166-176.		0
547	Understanding the characteristics of molecular targeting agents for proper usage. <i>Japanese Journal of Head and Neck Cancer</i> , 2012, 38, 399-402.	0.0	2
548	Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors. <i>Journal of the Advanced Practitioner in Oncology</i> , 2012, 3, 138-50.	0.2	9
549	Dermatologic Side Effects of Systemic Anticancer Therapy. , 2013, , 381-419.		1
550	Management of Skin Toxicity Associated with EGFR-targeted Monoclonal Antibody Treatment for Advanced Colorectal Cancer: A Single Center Experience. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Dermatology)</i> , 2013, 10, 101-105.	0.0	0
551	5. Application of Japanese Claims Database to Pharmacovigilance Activity in Pharmaceutical Industry; Analysis on Cancer Incidences and Usage of Anticancer Agents. <i>Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku</i> , 2013, 17, 145-153.	0.0	4
552	Assessment and Management of Skin Toxicity Associated with Anti-EGFR Monoclonal Antibody for Patients with Colorectal Cancer. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Dermatology)</i> , 2013, 10, 101-105.	0.0	0
555	Cutaneous Reactions to Tyrosine Kinase Inhibitors. , 2014, , 107-120.		0

#	ARTICLE	IF	CITATIONS
556	Drug-Induced Acne. , 2014, , 251-257.		0
557	Epidermal Growth Factor Inhibitor-induced Skin Toxicity. Nishinon Journal of Dermatology, 2015, 77, 203-209.	0.0	0
558	Skin toxicity of targeted therapy: Vemurafenib, first experiences from Montenegro. Sanamed, 2015, 10, 109-114.	0.1	0
560	Toxicity profile of lapatinib plus capecitabine in advanced breast cancer – a single-centre follow-up study. OnCOReview, 2015, 5, 164-168.	0.1	0
561	Targeted Cancer Therapy. Nishinon Journal of Dermatology, 2016, 78, 221-228.	0.0	0
562	Drug Combinations to Enhance Therapeutic Efficacy and Edit Out Side Effects and Resistance to Inhibition of Drug Resistance. Soft and Biological Matter, 2016, , 323-350.	0.3	0
563	Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 2016, 7, .	0.2	6
564	Living with the effects of cutaneous toxicities induced by treatment. Asia-Pacific Journal of Oncology Nursing, 2017, 4, 220-223.	0.7	2
565	Cetuximab in treatment of metastatic colorectal cancer: background and clinical observation. Meditsinskiy Sovet, 2018, , 32-41.	0.1	1
566	Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review). Oncology Reports, 2020, 45, 891-898.	1.2	6
567	Dermatological Toxicities of Targeted Therapy. , 2020, , 147-164.		1
568	Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1311-1325.	1.5	5
569	Achievements in targeted therapies. , 0, , 215-233.		0
570	Topical R1 and R2 Prophylactic Treatment of Acute Radiation Dermatitis in Squamous Cell Carcinoma of the Head and Neck and Breast Cancer Patients Treated With Chemoradiotherapy. Eplasty, 2015, 15, e25.	0.4	6
571	Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors. Journal of Medicine and Life, 2015, 8 Spec Issue, 57-61.	0.4	7
572	Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 2016, 7, 723-735.	0.2	4
574	Unraveling the differential impact of PAHs and dioxin-like compounds on AKR1C3 reveals the EGFR extracellular domain as a critical determinant of the AHR response. Environment International, 2022, 158, 106989.	4.8	15
575	Dermatological toxicity of EGFR inhibitors: pathogenetic rationale and an algorithm for acne-like rash correction. Oncogematologiya, 2021, 16, 50-58.	0.1	4

#	ARTICLE	IF	CITATIONS
576	Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. <i>Cancers</i> , 2021, 13, 5715.	1.7	6
577	Arzneimittlexantheme unter modernen zielgerichteten Therapien â€œ Immuncheckpointâ€•und EGFRâ€•inhibitoren. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1621-1645.	0.4	2
578	Drug eruptions with novel targeted therapies â€œ immune checkpoint and EGFR inhibitors. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1621-1643.	0.4	6
580	A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. <i>Supportive Care in Cancer</i> , 2021, 30, 2455.	1.0	1
581	Immune-Related Oral, Otolgic, and Ocular Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 399-416.	0.8	2
582	Assessment of Skin Toxicity in an inÂVtiro Reconstituted Human Epidermis Model Using Deep Learning. <i>American Journal of Pathology</i> , 2022, 192, 687-700.	1.9	6
583	Nail changes with chemotherapeutic agents and targeted therapies. <i>Indian Dermatology Online Journal</i> , 2022, 13, 13.	0.2	5
584	Dermatologic adverse events associated with epidermal growth factor receptor inhibitors: current concepts of interdisciplinary problem. <i>Opuholi Golovy I Sei</i> , 2022, 11, 97-109.	0.1	5
585	Severe stomatitis caused by osimertinib combined with gefitinib: A case report. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05396.	0.2	3
586	Reducing Acneiform Rash Induced by EGFR Inhibitors With Honeysuckle Therapy: A Prospective, Randomized, Controlled Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 835166.	1.6	2
587	Physiological Considerations for Modeling in vivo Antibody-Target Interactions. <i>Frontiers in Pharmacology</i> , 2022, 13, 856961.	1.6	11
588	Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and metaâ€•analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 526-539.	0.7	4
589	A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors. <i>Dermatologic Therapy</i> , 2022, , e15412.	0.8	3
590	Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: <i>VigiBaseÂ®</i> . <i>Therapie</i> , 2022, 77, 219-227.	0.6	3
591	Remodeling of dermal adipose tissue alleviates cutaneous toxicity induced by anti-EGFR therapy. <i>ELife</i> , 2022, 11, .	2.8	2
592	EGFR signaling pathway as therapeutic target in human cancers. <i>Seminars in Cancer Biology</i> , 2022, 85, 253-275.	4.3	61
593	A Generic Strategy to Generate Bifunctional Two-in-One Antibodies by Chicken Immunization. <i>Frontiers in Immunology</i> , 2022, 13, 888838.	2.2	5
594	Developing symptom management drugs. , 0, , 314-324.		0

#	ARTICLE	IF	CITATIONS
595	Cutaneous Toxicity in Oncologic Patients Receiving Epidermal Growth Factor Receptor Inhibitors.. Current Health Sciences Journal, 2021, 47, 516-522.	0.2	1
597	EGFR-targeting therapy as an evolving concept: learning from nimotuzumab clinical development. Chinese Clinical Oncology, 2014, 3, 5.	0.4	3
598	Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. Nature Communications, 2022, 13, 2530.	5.8	29
599	Prophylactic Effect of Nitric Oxide Donors on Rat Models of EGFR Inhibitor-Induced Cutaneous Toxicities. Journal of Investigative Dermatology, 2022, 142, 3052-3061.e8.	0.3	0
600	Management of dermatologic adverse events associated with tumor treating fields in patients with glioblastoma multiforme: A 27-case series. Asia-Pacific Journal of Oncology Nursing, 2022, 9, 100095.	0.7	1
601	Oncologic emergencies and urgencies: A comprehensive review. Ca-A Cancer Journal for Clinicians, 2022, 72, 570-593.	157.7	18
602	Development of (4-Phenylamino)quinazoline Alkylthiourea Derivatives as Novel NF- κ B Inhibitors. Pharmaceuticals, 2022, 15, 778.	1.7	2
603	Acquired perforating dermatosis induced by necitumumab. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	2
604	From EGFR kinase inhibitors to anti-inflammatory drugs: Optimization and biological evaluation of (4-(phenylamino)quinazoliny)-phenylthiourea derivatives as novel NF- κ B inhibitors. Bioorganic Chemistry, 2022, 127, 105977.	2.0	2
605	Sweet syndrome induced by epidermal growth factor receptor (EGFR) inhibitors. Indian Journal of Dermatology, Venereology and Leprology, 0, .	0.2	1
606	5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) for acneiform rash induced by erlotinib: a case report. Photodiagnosis and Photodynamic Therapy, 2022, , 102994.	1.3	1
607	Vandetanib-mediated photoinduced erythema multiforme: A case report and photobiological study. Photodermatology Photoimmunology and Photomedicine, 2023, 39, 276-278.	0.7	1
608	Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review. Frontiers in Oncology, 0, 12, .	1.3	1
609	The Toxicity of Osimertinib in Cancer Therapy. , 0, 6, 313-320.		0
610	A nonneglectable stereochemical factor in drug development: Atropisomerism. Chirality, 2022, 34, 1355-1370.	1.3	8
611	Neonatal cutaneous inflammatory syndrome associated with homozygous epidermal growth factor receptor mutation. Pediatric Dermatology, 2023, 40, 171-175.	0.5	1
612	Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors. Supportive Care in Cancer, 0, , .	1.0	0
613	Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates. Pharmaceuticals, 2022, 14, 1917.	2.0	5

#	ARTICLE	IF	CITATIONS
614	Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	0
615	Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
616	Combination of available topical beta-blockers and antibiotic ointment for epidermal growth factor receptor tyrosine kinase inhibitor-induced paronychia and pseudopyogenic granulomas in Taiwan. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211220.	0.5	2
617	The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy. <i>Journal of Cutaneous Pathology</i> , 2023, 50, 72-95.	0.7	2
618	Cutaneous Reactions to Oncologic Targeted Therapy. <i>Updates in Clinical Dermatology</i> , 2022, , 303-316.	0.1	0
619	Other Drug-Induced Inflammatory Skin Reactions. <i>Updates in Clinical Dermatology</i> , 2022, , 191-202.	0.1	0
620	Prognostic factors for the development of acneiform eruptions in patients on epidermal growth factor receptor inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 869-870.	0.6	0
621	Identification of immune-related mechanisms of cetuximab induced skin toxicity in colorectal cancer patients. <i>PLoS ONE</i> , 2022, 17, e0276497.	1.1	4
622	Patient noncompliance as the cause of skin toxicity in capecitabine therapy. , 2022, 2, 55-58.		0
624	The Riddle of Cetuximab-Related Skin Toxicity: 1H-NMR Sebum Analysis Revealed Dynamic Lipid Alterations Associated with Skin Toxicity Development in Metastatic Colorectal Cancer Patients. <i>Cancers</i> , 2022, 14, 5308.	1.7	2
625	Effective and enduring surgical treatment for targeted therapy-related paronychia: A retrospective study. <i>Medicine (United States)</i> , 2022, 101, e31208.	0.4	1
627	Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. <i>Trends in Immunology</i> , 2022, 43, 932-946.	2.9	22
628	Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, 328-339.	1.3	7
629	Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2023, 80, 129084.	1.0	3
630	The use of epidermal growth factor in dermatological practice. <i>International Wound Journal</i> , 2023, 20, 2414-2423.	1.3	9
631	Management of the adverse effects of targeted therapy for cancer. <i>Journal of the Korean Medical Association</i> , 2023, 66, 105-111.	0.1	0
632	EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects. <i>Anais Brasileiros De Dermatologia</i> , 2023, , .	0.5	1
633	Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------